Mehta, R., Hara, H., Moehler, M. H., Tang, W., Wang, K., Zhang, Z., Chirikov, V., Quan, W., Zhan, L. (2026). Quality-adjusted survival comparison for tislelizumab (TIS) + chemotherapy (CT) versus placebo (PBO) + CT as first-line (1L) treatment in gastric/gastroesophageal junction adenocarcinoma (GC/GEJC) patients with peritoneal metastasis (PM): Long-term follow-up from RATIONALE-305.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.4034